Results 101 to 110 of about 820 (140)

Emicizumab in pediatric hemophilia a: a case study [PDF]

Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”, Chişinău, Republica MoldovaIntroduction. The development of inhibitors that neutralize the function of clotting factor VIII is currently the most challenging complication associated ...
Miaun, Livia
core  

Implementing an assay detecting anti-drug antibody against emicizumab: experience from one center in France

Background Emicizumab is an antibody that mimics the function of factor (F)VIII and has been approved for prophylaxis in hemophilia A patients. However, the development of anti-drug antibodies (ADA) against emicizumab, although rare, can impair its ...
Lenting, Peter J, Lasne, Dominique, Auditeau, Claire, Valsecchi, Carla, Bentounes, Nun Kalim, Harroche, Annie, Peyvandi, Flora, Bally, Cécile, Borgel, Delphine, Le-Goff, Amandine   +9 more
core   +1 more source

PO86 | Emicizumab in patients with moderate hemophilia A and severe bleeding phenotype: single-center real-world experience

Bleeding, Thrombosis and Vascular Biology
Background and Aims: The role of prophylaxis in moderate hemophilia A (HA) patients is less clear than in severe HA, given their variable bleeding phenotype.
doaj   +1 more source

CO31 | Immune system profiling in FVIII-treated and emicizumab-treated pediatric HA patients

Bleeding, Thrombosis and Vascular Biology
Background: Prophylactic treatments to prevent bleeding are considered the standard therapy in Hemophilia A (HA) and inhibitor formation is the main complication of FVIII infusion.
doaj   +1 more source

An Institutional Experience With Emicizumab In Pediatric Patients With Heophilia A

, 2020
Background: Emicizumab is a recombinant, humanized, bispecific monoclonal antibody that substitutes for the function of FVIII by binding to activated factor IX and X.
Ratte, Janet, Jung, Lisa, Abraham, Shirley, Lowe, Valerie   +3 more
core  

Emicizumab for severe von willebrand disease (VWD): The (EmiVWD) study enrollment 2025

Background and Significance: Von Willebrand Disease (VWD) is the most common inherited bleeding disorder affecting up to 0.1-1% of the population, typically characterized by mucocutaneous bleeding.
Kreitzer, Sarah, Roberts, Jonathan, Cockrell, Erin, Mullery, Amanda, Tarantino, Michael, Corrales-Medina, Fernando, Chien, May, Kruse-Jarres, Rebecca, Gupta, Sweta   +8 more
core   +1 more source

Emicizumab for haemophilia A.

Australian prescriber
openaire   +1 more source

Emicizumab: A Review in Haemophilia A

Drugs, 2019
Emicizumab (Hemlibra®), a recombinant, humanized, bispecific monoclonal antibody, restores the function of missing activated factor VIII (FVIII) by bridging FIXa and FX to facilitate effective haemostasis in patients with haemophilia A. Subcutaneous emicizumab is approved in several countries, including in the USA and Japan, for the routine prophylaxis
Hannah A. Blair (5008301)
openaire   +3 more sources

Functional determination of emicizumab in presence of factor VIII activity

Journal of Thrombosis and Haemostasis, 2023
Background: Accurate measurement of emicizumab in the presence of factor (F) VIII is required in patients with severe hemophilia A treated with emicizumab, as well as additional need for FVIII substitution or emicizumab prophylaxis in patients with ...
Claudia Klein, Bernd Pötzsch
exaly   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Emicizumab

Reactions Weekly
Stephanie J. Phelps, Tracy M. Hagemann, Kelley R. Lee   +2 more
  +12 more sources